Akèy › Dematit atopik (Ekzema) › Alabama
Etid klinik pou Dematit atopik (Ekzema) nan Alabama
9 etid pou Dematit atopik (Ekzema) ap chèche patisipan nan sit nan Alabama.
Vil nan Alabama
Tèks ofisyèl etid la (Anglè)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham
- River Region Dermatology and Laser- Site Number : 8400041, Montgomery
Ap rekriteEtid obsèvasyon
Laj 12 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Birmingham
- Novartis Investigative Site, Birmingham
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Birmingham
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Cahaba Dermatology & Skin Health Center, LLC, Birmingham
Ap rekriteFaz 1Volontè an sante akeyi
Laj 18 a 65 · Tout sèks · Mizajou Sep 25, 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Cahaba Dermatology & Skin Health Center, Birmingham
Ap rekriteFaz 3
Laj 2 a 11 · Tout sèks · Mizajou Sep 25, 2026 · NCT06807281A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- AllerVie Clinical Research, Birmingham
- Cahaba Dermatology and Skin Health Center, Birmingham
Ap rekriteFaz 2
Laj 18 a 65 · Tout sèks · Mizajou Aug 28, 2026 · NCT07599813A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
- Leo Pharma Investigational site, Birmingham
Ap rekriteFaz 3
6 Months – 11 Years · Tout sèks · Mizajou Jul 7, 2026 · NCT06311682A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham
Ap rekriteFaz 3
Laj 18 a 63 · Tout sèks · Mizajou Jul 6, 2026 · NCT06389136A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Allervie Clinical Research, Birmingham
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT05995964Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.